Cargando…
Adjuvant therapeutic potential of tonabersat in the standard treatment of glioblastoma: A preclinical F98 glioblastoma rat model study
PURPOSE: Even with an optimal treatment protocol, the median survival of glioblastoma (GB) patients is only 12–15 months. Hence, there is need for novel effective therapies that improve survival outcomes. Recent evidence suggests an important role for connexin (Cx) proteins (especially Cx43) in the...
Autores principales: | De Meulenaere, Valerie, Bonte, Ellen, Verhoeven, Jeroen, Kalala Okito, Jean-Pierre, Pieters, Leen, Vral, Anne, De Wever, Olivier, Leybaert, Luc, Goethals, Ingeborg, Vanhove, Christian, Descamps, Benedicte, Deblaere, Karel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6802836/ https://www.ncbi.nlm.nih.gov/pubmed/31634381 http://dx.doi.org/10.1371/journal.pone.0224130 |
Ejemplares similares
-
Technical feasibility of [(18)F]FET and [(18)F]FAZA PET guided radiotherapy in a F98 glioblastoma rat model
por: Verhoeven, Jeroen, et al.
Publicado: (2019) -
Species-dependent extracranial manifestations of a brain seeking breast cancer cell line
por: De Meulenaere, Valerie, et al.
Publicado: (2018) -
The Path Toward PET-Guided Radiation Therapy for Glioblastoma in Laboratory Animals: A Mini Review
por: Donche, Sam, et al.
Publicado: (2019) -
In vivo selection of the MDA-MB-231br/eGFP cancer cell line to obtain a clinically relevant rat model for triple negative breast cancer brain metastasis
por: De Meulenaere, Valerie, et al.
Publicado: (2020) -
Assessment of the effect of therapy in a rat model of glioblastoma using [(18)F]FDG and [(18)F]FCho PET compared to contrast-enhanced MRI
por: Bolcaen, Julie, et al.
Publicado: (2021)